Cited by 955Immunotherapy and Immune ResponsesRNA modifications and cancerCancer Immunotherapy and Biomarkers

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells

Open access
Han, Dali, Liu, Jun, Chen, Chuanyuan, Dong, Lihui, Liu, Yi, Chang, Renbao, Huang, Xiaona, Liu, Yuanyuan +7 more·2019·Nature

Abstract

There is growing evidence that tumour neoantigens have important roles in generating spontaneous antitumour immune responses and predicting clinical responses to immunotherapies 1,2. Despite the presence of numerous neoantigens in patients, complete tumour elimination is rare, owing to failures in mounting a sufficient and lasting antitumour immune response 3,4. Here we show that durable neoantigen-specific immunity is regulated by mRNA N 6-methyadenosine (m 6 A) methylation through the m 6 A-binding protein YTHDF1 5. In contrast to wild-type mice, Ythdf1-deficient mice show an elevated antigen-specific CD8+ T cell antitumour response. Loss of YTHDF1 in classical dendritic cells enhanced the cross-presentation of tumour antigens and the cross-priming of CD8+ T cells in vivo. Mechanistically, transcripts encoding lysosomal proteases are marked by m 6 A and recognized by YTHDF1. Binding of YTHDF1 to these transcripts increases the translation of lysosomal cathepsins in dendritic cells, and inhibition of cathepsins markedly enhances cross-presentation of wild-type dendritic cells. Furthermore, the therapeutic efficacy of PD-L1 checkpoint blockade is enhanced in Ythdf1-/- mice, implicating YTHDF1 as a potential therapeutic target in anticancer immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-0916-x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., Bissonnette, M. B., Shen, B., Weichselbaum, R. R., Xu, M. M., & He, C.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Howard Hughes Medical Institute (US)
  • Peking University (CN)
  • University of Chicago (US)
  • State Key Laboratory of Reproductive Medicine (CN)
Corresponding author
  • Han, Dali
  • Xu, Meng Michelle
  • He, Chuan
Venue
Nature
Published
2019-02
Volume
566
Issue
7743
Pages
270-274
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2911349862
Cited by
955
References
40
Citations by year
2026: 68 · 2025: 84 · 2024: 116 · 2023: 152 · 2022: 221 · 2021: 195 · 2020: 90 · 2019: 29
FWCI
53.68
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Human Genome Research Institute (RM1HG008935)
  • National Cancer Institute (U01CA217078)
  • National Institute of General Medical Sciences (R01GM113194)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
YTHDF1, dendritic cells, neoantigens, antitumor immunity, cross-presentation, cathepsins, lysosomal proteases, translational regulation, PD-L1 blockade, cancer immunotherapy, tumor antigen presentation
MeSH terms
Adenosine, Animals, Antigens, Neoplasm, Binding Sites, Cathepsins, Dendritic Cells, Female, Humans, Methylation, Mice, Inbred C57BL, Neoplasms, Proteins, RNA, Messenger, Protein Biosynthesis, RNA-Binding Proteins, Antigen Presentation, CD8-Positive T-Lymphocytes, Cross-Priming, Mice, Transcriptome, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review